Day: September 22, 2025

Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and Taiwan Sovargen receives upfront payment and is eligible for future milestone-dependent payments and

FORT WASHINGTON, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) — Coventry, the leader and creator of the secondary market for life insurance, is proud to recognize Life Insurance Awareness Month by reaffirming its unwavering commitment to making life insurance not just an essential asset, but also more valuable, more flexible and

Louis Cooper Chief Commercial Officer Axi ( CCO) Louis Cooper Chief Commercial Officer Axi ( CCO) SYDNEY, Sept. 22, 2025 (GLOBE NEWSWIRE) — Axi, a leading global online trading and fintech company, today announces the retirement of Louis Cooper, Chief Commercial Officer. Louis will formally step down from his executive

Governing Board approves major financing package as institution launches inaugural Euro benchmark bond OPEC Fund President Abdulhamid Alkhalifa OPEC Fund President Abdulhamid Alkhalifa VIENNA, Sept. 22, 2025 (GLOBE NEWSWIRE) — The OPEC Fund for International Development (the OPEC Fund) announced the approval of more than US$1 billion in new development

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sable Offshore Corp. (NYSE: SOC): (1) between May 19, 2025 and June 3, 2025, both dates inclusive (the “Class Period”); and/or (2) pursuant and/or traceable to Sable’s May

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the